While the results from persevERA were not statistically significant, they may support using oral SERDs for patients with ER+/HER2– breast cancer.
Mabel Mardones, MD
Advertisement
Articles by Mabel Mardones, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Navigating the RCC Adjuvant Landscape: Examining the Phase 3 RAMPART Trial
2
Radiation Oncology Trials You May Have Missed at ASCO 2026
3
Menin Inhibition Shows Utility in Heterogenous AML Population
4
81 A First-in-Human Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients Who Have Advanced Solid Tumors With ERBB2 Genetic Alterations or HER2 Overexpression
5